Actuate Therapeutics, Inc. (ACTU) Price & Analysis

Compare

22 Followers

ACTU Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.47 - $11.99

Previous CloseN/A

Volume10.16K

Average Volume (3M)74.63K

Market Cap

$160.15M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.09

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.41

Shares Outstanding23,243,328

10 Day Avg. Volume70,132

30 Day Avg. Volume74,630

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$20.00

Price Target Upside190.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical DataUpdated elraglusib data presented at the 2025 ASCO meeting showed significant improvement in survival rates for patients with metastatic pancreatic adenocarcinoma.

Financial PerformanceThe recent equity offering resulted in gross proceeds of $17.25M, which could fund operations through planned submission of regulatory applications with the FDA and EMA.

Regulatory ProgressThe company intends to submit the elraglusib NDA under the Real-Time Oncology Review program which allows not only for a rolling submission but also for a faster review process.

Bears Say

Financial RisksFor 2Q25, the company reported no revenues, in-line with consensus estimates, and a net loss of $0.30 per diluted share.

Potential RisksRisks to the Buy rating include financial, clinical, manufacturing, legal and intellectual property, regulatory, competition, commercial, and pipeline challenges.

Actuate Therapeutics, Inc. News

Actuate announces corporate update on regulatory path for elraglusib

Actuate Therapeutics (ACTU) announced a corporate update on the regulatory path for elraglusib in pancreatic cancer and anticipated...

7d ago

ACTU

Actuate prices 2.14M shares at $7.00 in underwritten public offering

Actuate Therapeutics (ACTU) priced an underwritten public offering of 2,142,858 shares of its common stock at an offering...

19d ago

ACTU

Actuate Therapeutics 2.142M share Secondary priced at $7.00

acted as lead book running manager for the offering. Published first on TheFly – the ultimate source for...

19d ago

ACTU

Actuate Therapeutics announces common stock offering, no amount given

Actuate Therapeutics (ACTU) announced that it intends to offer and sell shares of its common stock in an...

20d ago

ACTU

Actuate Therapeutics files $250M mixed securities shelf

16:30 EDT Actuate Therapeutics (ACTU) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

27d ago

ACTU

Actuate Therapeutics Receives Buy Rating Amid Strategic Advancements and Financial Strengthening

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Actuate Therapeutics, Inc., retaining the price target...

7d ago

ACTU

Actuate Therapeutics Announces Public Offering of Shares

Actuate Therapeutics, Inc. ( ($ACTU) ) has issued an update. On September 10, 2025, Actuate Therapeutics, Inc. announced...

19d ago

ACTU

Actuate Therapeutics initiated with a Buy at B. Riley

B. Riley initiated coverage of Actuate Therapeutics (ACTU) with a Buy rating and $20 price target The firm...

1M ago

ACTU

Actuate Therapeutics, Inc.: Strategic Regulatory Advances and Promising Clinical Data Drive Buy Rating

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on Actuate Therapeutics, Inc.. The associated price...

1M ago

ACTU

Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial

Actuate Therapeutics (ACTU) announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte’s (INCY)...

2M ago

ACTU

INCY

Actuate Therapeutics files to sell 1.33M shares of common stock for holders

16:02 EDT Actuate Therapeutics (ACTU) files to sell 1.33M shares of common stock for holders Published first on...

2M ago

ACTU

Promising Clinical Developments and Valuation Support Buy Rating for Actuate Therapeutics

H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on ACTU stock, giving a Buy rating on...

2M ago

ACTU

Actuate Therapeutics announces end of Phase 1 portion of elraglusib study

Actuate Therapeutics (ACTU) announced the end of the Phase 1 portion of its clinical study evaluating elraglusib monotherapy...

2M ago

ACTU

Actuate Therapeutics Secures $4.7M in Private Placement

Actuate Therapeutics, Inc. ( ($ACTU) ) has shared an update. On June 25, 2025, Actuate Therapeutics, Inc. entered...

3M ago

ACTU

ACTU FAQ

What was Actuate Therapeutics, Inc.’s price range in the past 12 months?

Actuate Therapeutics, Inc. lowest stock price was $5.47 and its highest was $11.99 in the past 12 months.

What is Actuate Therapeutics, Inc.’s market cap?

Actuate Therapeutics, Inc.’s market cap is $160.15M.

When is Actuate Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Actuate Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Actuate Therapeutics, Inc. overvalued?

According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actuate Therapeutics, Inc. pay dividends?

Actuate Therapeutics, Inc. does not currently pay dividends.

What is Actuate Therapeutics, Inc.’s EPS estimate?

Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actuate Therapeutics, Inc. have?

Actuate Therapeutics, Inc. has 23,243,328 shares outstanding.

What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ACTU

Actuate Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

302.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

ACTU Stock 12 Month Forecast

Average Price Target

$20.00

▲(190.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","9":"$9","13":"$13","17":"$17","21":"$21"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9,13,17,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,9.569230769230769,10.438461538461539,11.307692307692307,12.176923076923076,13.046153846153846,13.915384615384614,14.784615384615384,15.653846153846153,16.52307692307692,17.392307692307693,18.26153846153846,19.130769230769232,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,9.569230769230769,10.438461538461539,11.307692307692307,12.176923076923076,13.046153846153846,13.915384615384614,14.784615384615384,15.653846153846153,16.52307692307692,17.392307692307693,18.26153846153846,19.130769230769232,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.7,9.569230769230769,10.438461538461539,11.307692307692307,12.176923076923076,13.046153846153846,13.915384615384614,14.784615384615384,15.653846153846153,16.52307692307692,17.392307692307693,18.26153846153846,19.130769230769232,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.92,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.83,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.92,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.96,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":9.03,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.24,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.7,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >